A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
ClinicalTrials.gov NCT05229900
Research payments
$1,237,483
Through program year 2023, $1,237,483 in research payments was reported against A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors, across 251 payments, paid by Seattle Genetics, Inc..
- Paid by
- Seattle Genetics, Inc.
- ClinicalTrials.gov
- NCT05229900
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $969,462 | 191 |
| 2022 | Research | $268,021 | 60 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Justin Call West Valley City, UT Named on 82 payments
- Cesar Perez Miami, FL Named on 66 payments
- Nehal Lakhani Grand Rapids, MI Named on 52 payments
- Kathleen Moore Oklahoma City, OK Named on 24 payments
- Alexander Spira Fairfax, VA Named on 15 payments
- Patricia Lo Russo New Haven, CT Named on 7 payments
- Li Ge Fresno, CA Named on 4 payments
- Christopher Perkins Fresno, CA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.